Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chagnac, Y.
Right arrow Articles by Goldhammer, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chagnac, Y.
Right arrow Articles by Goldhammer, Y.
NEUROLOGY 1985;35:1219
© 1985 American Academy of Neurology

Myasthenic crisis after intraxenous administration of iodinated contrast agent

Yael Chagnac, MD, Moshe Hadani, MD and Yohanan Goldhammer, MD

Departments of Neurology (Drs. Chagnac and Goldhammer) and Neurosurgery (Dr. Hadani), The Chaim Sheba Medical Center and Tel-Aviv University Sackler School of Medicine, Tel-Hashomer, Israel.

Two women with myasthenia gravis became apneic immediately after IV injection of iodinated contrast material for CT. Aggravation of myasthenia continued for days after this initial reaction.

Address correspondence and reprint requests to Dr. Chagnac, Department of Neurology, The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.

Accepted for publication November 14, 1984.




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
E. T. Wittbrodt
Drugs and Myasthenia Gravis: An Update
Arch Intern Med, February 24, 1997; 157(4): 399 - 408.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.